Training activity information
Details
Select, perform and interpret tests for viral causes of central nervous system infection using the following techniques and suggest options for management:
- Microscopy and cell count
- Molecular assays
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- How will this DTA contribute to your understanding of the role of molecular assays in diagnosing viral CNS infections?
- What are the common viral pathogens associated with CNS infections?
- What is your understanding of microscopy and cell count on CSF and the application of molecular assays for detecting these viruses?
- What specific skills in interpreting PCR results for common neurotropic viruses do you hope to develop?
- How will you learn about the clinical utility of viral PCR in CSF compared to other diagnostic methods?
- How will this activity enhance your understanding of suggesting management options for viral CNS infections, including the use of antiviral agents where available?
- How will you prepare for this DTA?
- Will you review the common viral targets in CNS infection PCR panels?
- Will you discuss with your training officer the interpretation of negative PCR results in suspected viral encephalitis or meningitis?
- What challenges might arise in interpreting a positive viral PCR result in the absence of other clinical findings?
- How will you consider the sensitivity and specificity of different molecular assays?
- How do you feel about the increasing importance of molecular diagnostics in the investigation of CNS infections?
In action
- What specific viral CNS infection tests are you currently performing or interpreting (e.g., CSF cell count and differential, PCR for herpes simplex virus, enterovirus)?
- How are you approaching the execution or interpretation of these assays? Why are you doing it this way (e.g., understanding the typical CSF profile in viral meningitis, the high sensitivity of PCR for detecting viral DNA/RNA)?
- What decisions are you making regarding the interpretation of a positive PCR result in the clinical context?
- What aspects of performing or interpreting these tests feel intuitive to you, and what requires more conscious effort (e.g., understanding the limitations of cell count alone in diagnosing viral CNS infections, interpreting cycle threshold values in PCR)?
- How effective are your current actions in obtaining or interpreting clinically relevant results for viral CNS infections?
- What challenges are you facing during the process (e.g., understanding the implications of a negative PCR result despite clinical suspicion)?
- What can you learn about diagnosing viral CNS infections and the importance of molecular diagnostics as the activity unfolds?
- How does this activity connect to your understanding of viral meningitis and encephalitis?
- Are there alternative approaches you could be considering if initial tests are negative but clinical suspicion remains high (e.g., requesting PCR for a broader range of neurotropic viruses, considering other diagnostic modalities)?
- What support or guidance might you need in this moment from a senior colleague or the training officer regarding the interpretation of PCR results in the context of the patient’s clinical presentation?
- Are you working within your scope of practice when selecting, performing, and interpreting these tests and considering management options?
On action
- Begin by summarising the key points of the experience working with CNS samples for viral investigations.
- What were the most significant observations regarding sample handling, the role of cell counts in the context of viral CNS infection, or the performance/interpretation of molecular assays for neurotropic viruses?
- What skills or knowledge did you develop or improve through this DTA, specifically in performing microscopy/cell counts on CSF, using molecular assays for viral CNS pathogens, interpreting molecular results (e.g., viral loads, qualitative detection), or suggesting management based on viral findings?
- Were there any unexpected challenges (e.g., interpreting results from immunocompromised patients, dealing with low viral copy numbers) or successes? What did you learn from these?
- In what ways did your ‘reflection-in-action’ influence your approach during the activity, such as considering the clinical presentation when interpreting molecular results?
- What areas for continued development have been identified, perhaps concerning the interpretation of quantitative viral loads or understanding the spectrum of viruses tested for CNS infections?
- How can you apply the learning from this activity to your routine practice when handling CNS samples and reporting viral results?
- Identify the specific actions or ‘next steps’ you will take to enhance your understanding of viral CNS diagnostics. What support or resources might you need to further develop in these areas?
Beyond action
- Revisit your initial reflect-on-action notes for this DTA. What additional insights have you gained since the initial reflection?
- Has discussing viral encephalitis or meningitis cases at MDT meetings or with neurologists/virologists altered your perspective on the clinical presentation and interpretation of molecular results?
- How did this specific viral CNS testing experience compare to bacterial or fungal CNS testing?
- What unique challenges (e.g., performing molecular tests on CSF, understanding the significance of viral detection) have you identified with viral CNS samples?
- Have you discussed viral CNS diagnostics, management, or molecular testing during professional discussions? What new perspectives did this bring?
- How have the skills (e.g., performing molecular assays on CSF, interpreting viral PCR results, understanding the role of molecular testing in neurological infections) you developed during this DTA influenced your approach to molecular testing on other critical samples?
- Have you applied the learning from this DTA, such as recognising the importance of rapid molecular testing for guiding antiviral treatment or the challenges of interpreting results in complex cases, to other aspects of your microbiology practice?
- How does the learning from this DTA contribute to your preparedness for interpreting molecular results from critical samples?
- What transferable skills in applying molecular diagnostics to critical samples, interpreting complex viral assay results, and contributing to the management of severe viral infections, developed through this DTA, will be invaluable throughout your training and beyond?
- Identify clear actions for continued development related to viral CNS diagnostics, molecular techniques, or liaison with clinical teams based on your cumulative experiences and reflections.
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 1 |
Outcome
Select and perform tests to investigate common infections from a range of sample types following guidance and fulfilling health and safety requirements |
| # 2 |
Outcome
Interpret the results of tests used to investigate common infections from a range of sample types with consideration of laboratory quality assurance and quality control |
| # 3 |
Outcome
Identify options for management of common infections based on test results and clinical context, considering infection control, guidelines and public health requirements |
| # 4 |
Outcome
Perform and interpret molecular techniques for the investigation of common infections following guidance and fulfilling health and safety requirements |